Market Overview

A Peek Into The Market Before The Trading Starts

Related VHS
Benzinga's Top Downgrades
Benzinga Market Primer: Wednesday, August 21: FOMC Minutes Continue To Drive Markets
Related FLR
Earnings Scheduled For October 30, 2014
Fluor And Technip Awarded RAPID Refinery Facilities Project In Malaysia
How TRIA Renewal Could Impact Construction (Fox Business)

Pre-open movers US stock futures are higher this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average surged 51 points to 14,639.00 and S&P 500 index futures rose 6.50 points to 1,572.70. Nasdaq 100 futures gained 12.75 points to 2,856.75.

A Peek Into Global Markets European markets were higher today. The STOXX Europe 600 Index surged 1.12%, London's FTSE 100 index gained 0.83%, French CAC 40 Index climbed 1.42% and German DAX 30 index rose 1.41%.

Asian markets ended mostly lower, with Japan's Nikkei Stock Average falling 0.72%, China's Shanghai Composite dropping 0.19% and Australia's ASX/S&P500 falling 0.38%. Hong Kong's Hang Seng Index gained 0.21% and India's Sensex surged 0.48%.

Broker Recommendation Analysts at Deutsche Bank downgraded Vanguard Health Systems (NYSE: VHS) from “buy” to “hold.” The target price for Vanguard Health has been raised from $16.50 to $21.

Vanguard Health's shares closed at $20.70 yesterday.

Breaking news

  • Fluor (NYSE: FLR) announced today that it was awarded a contract by Sasol Technology (Pty.) Ltd. to perform basic engineering services associated with the Natref Clean Fuels 2 Project in Sasolburg, South Africa. To read the full news, click here.
  • Lennar (NYSE: LEN) reported a drop in its second-quarter net income. To read the full news, click here.
  • Rite Aid (NYSE: RAD) today announced the completion of a portion of its previously announced debt refinancing transactions that extends the maturity on a portion of Rite Aid's outstanding indebtedness and lowers interest expense. To read the full news, click here.
  • Vical (NASDAQ: VICL) and Astellas Pharma today announced the initiation of a multinational Phase 3 registration trial of ASP0113 (TransVax™), in approximately 500 hematopoietic cell transplant (HCT) recipients. To read the full news, click here.

Posted-In: Deutsche Bank US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (FLR + LEN)

Around the Web, We're Loving...

Get Benzinga's Newsletters